Point72 Asia Singapore Pte. Ltd. Buys New Position in Karyopharm Therapeutics Inc. (NASDAQ:KPTI)

Point72 Asia Singapore Pte. Ltd. bought a new position in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 165,318 shares of the company’s stock, valued at approximately $143,000. Point72 Asia Singapore Pte. Ltd. owned approximately 0.13% of Karyopharm Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently added to or reduced their stakes in the business. Cubist Systematic Strategies LLC bought a new stake in shares of Karyopharm Therapeutics in the 2nd quarter valued at $494,000. Acadian Asset Management LLC bought a new stake in Karyopharm Therapeutics in the second quarter valued at $167,000. Point72 DIFC Ltd acquired a new position in shares of Karyopharm Therapeutics during the second quarter valued at about $31,000. Finally, Ikarian Capital LLC boosted its position in shares of Karyopharm Therapeutics by 2.3% during the 1st quarter. Ikarian Capital LLC now owns 409,355 shares of the company’s stock worth $618,000 after purchasing an additional 9,355 shares in the last quarter. 66.44% of the stock is owned by institutional investors and hedge funds.

Karyopharm Therapeutics Stock Up 2.5 %

Shares of NASDAQ:KPTI opened at $0.72 on Friday. The business’s 50 day moving average is $0.81 and its 200 day moving average is $1.01. Karyopharm Therapeutics Inc. has a 12-month low of $0.62 and a 12-month high of $1.95. The stock has a market cap of $90.21 million, a price-to-earnings ratio of -0.57 and a beta of 0.20.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.09. The firm had revenue of $42.79 million for the quarter, compared to analysts’ expectations of $36.07 million. As a group, equities research analysts expect that Karyopharm Therapeutics Inc. will post -0.93 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts recently commented on KPTI shares. StockNews.com raised Karyopharm Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. HC Wainwright reaffirmed a “buy” rating and set a $7.00 target price on shares of Karyopharm Therapeutics in a research report on Wednesday, August 7th. Robert W. Baird reduced their price target on shares of Karyopharm Therapeutics from $8.00 to $5.00 and set an “outperform” rating for the company in a research report on Wednesday, August 7th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $3.00 price target on shares of Karyopharm Therapeutics in a research note on Wednesday, August 7th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Karyopharm Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $4.80.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).